STAT+: New CAR-T company, Brainchild Bio, will focus first on brain tumors in children
STAT
DECEMBER 5, 2023
About a decade ago, Mike Jensen, a pediatric oncologist at Seattle Children’s hospital, licensed to a startup his designs for a powerful new type of therapy, called CAR-T, that would re-engineer a child’s own immune cells to target cancer. The deal proved be a mixed blessing. But it was never approved for childhood cancer.
Let's personalize your content